Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab With or Without Induction Chemotherapy Followed by Chemoradiotherapy in Unresectable Locally Advanced ESCC
NCT06510660Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Clinical Complete Response at 6 months. Started Apr 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06510660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510660.